A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naive Adults With Early Active Rheumatoid Arthritis

Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naive Adults With Early Active Rheumatoid Arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jan 2017

At a glance

  • Drugs Certolizumab pegol (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms C-EARLY
  • Sponsors UCB Pharma SA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Nov 2016 Analysis of clinical responses and workplace/household productivity improvements in patient-reported outcomes (n=655) were presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 10 May 2016 Results published in the Annals of the Rheumatic Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top